{"id":186332,"date":"2017-04-05T16:22:01","date_gmt":"2017-04-05T20:22:01","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/fda-approves-dupixent-to-treat-moderate-to-severe-eczema-clinical-advisor\/"},"modified":"2017-04-05T16:22:01","modified_gmt":"2017-04-05T20:22:01","slug":"fda-approves-dupixent-to-treat-moderate-to-severe-eczema-clinical-advisor","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/eczema\/fda-approves-dupixent-to-treat-moderate-to-severe-eczema-clinical-advisor\/","title":{"rendered":"FDA approves Dupixent to treat moderate-to-severe eczema &#8211; Clinical Advisor"},"content":{"rendered":"<table border=\"0\" cellpadding=\"2\" cellspacing=\"7\" style=\"vertical-align:top;\"><tr><td width=\"80\" align=\"center\" valign=\"top\"><font style=\"font-size:85%;font-family:arial,sans-serif\"><a href=\"http:\/\/news.google.com\/news\/url?sa=t&amp;fd=R&amp;ct2=us&amp;usg=AFQjCNGEXpRBvyP8mUj4etv6HO5UDQHnHg&amp;clid=c3a7d30bb8a4878e06b80cf16b898331&amp;cid=52779447397161&amp;ei=6FHlWJiJJJfD3QGnhIqIAQ&amp;url=http:\/\/www.clinicaladvisor.com\/dermatology-information-center\/fda-approves-dupixent-to-treat-eczema\/article\/647240\/\"><img loading=\"lazy\" decoding=\"async\" src=\"\/\/t1.gstatic.com\/images?q=tbn:ANd9GcQ6mEkP657KOfMioM8LP7QGQlvz_iH5_H-cmBf4AgKIFlJuFKUg_f9g0szSfuhnAhyDejU-BeQi\" alt=\"\" border=\"1\" width=\"80\" height=\"80\" style=\"padding-left:10px; padding-right: 10px;\"><br><font size=\"-2\">Clinical Advisor<\/font><\/a><\/font><\/td><td valign=\"top\" class=\"j\"><font style=\"font-size:85%;font-family:arial,sans-serif\"><div style=\"padding-top:0.8em;\"><img alt=\"\" height=\"1\" width=\"1\" style=\"padding-left:10px; padding-right: 10px;\"><\/div><div class=\"lh\"><a href=\"http:\/\/news.google.com\/news\/url?sa=t&amp;fd=R&amp;ct2=us&amp;usg=AFQjCNGEXpRBvyP8mUj4etv6HO5UDQHnHg&amp;clid=c3a7d30bb8a4878e06b80cf16b898331&amp;cid=52779447397161&amp;ei=6FHlWJiJJJfD3QGnhIqIAQ&amp;url=http:\/\/www.clinicaladvisor.com\/dermatology-information-center\/fda-approves-dupixent-to-treat-eczema\/article\/647240\/\"><b>FDA approves Dupixent to treat moderate-to-severe <b>eczema<\/b><\/b><\/a><br><font size=\"-1\"><b><font color=\"#6f6f6f\">Clinical Advisor<\/font><\/b><\/font><br><font size=\"-1\">(HealthDay News)  Dupixent (dupilumab) has been approved by the US Food and Drug Administration to treat moderate-to-severe <b>eczema<\/b> that isn't well controlled by topical medication. The active ingredient in Dupixent is an antibody (dupilumab) that&nbsp;...<\/font><br><font size=\"-1\"><a href=\"http:\/\/news.google.com\/news\/url?sa=t&amp;fd=R&amp;ct2=us&amp;usg=AFQjCNGLzAf9UH8XAJpAKliDqAtPK-l_iA&amp;clid=c3a7d30bb8a4878e06b80cf16b898331&amp;cid=52779447397161&amp;ei=6FHlWJiJJJfD3QGnhIqIAQ&amp;url=http:\/\/www.sciencetimes.com\/articles\/11468\/20170402\/dupixent-eczemas-powerful-cure-approved-fda.htm\">Dupixent: Eczema's Most Powerful Cure, Approved By FDA ...<\/a><font size=\"-1\" color=\"#6f6f6f\"><nobr>Science Times<\/nobr><\/font><\/font><br><font size=\"-1\"><a href=\"http:\/\/news.google.com\/news\/url?sa=t&amp;fd=R&amp;ct2=us&amp;usg=AFQjCNGFfE7wj7khb-ehmnfPiofMRepR2Q&amp;clid=c3a7d30bb8a4878e06b80cf16b898331&amp;cid=52779447397161&amp;ei=6FHlWJiJJJfD3QGnhIqIAQ&amp;url=https:\/\/www.europeanpharmaceuticalreview.com\/50291\/news\/industry-news\/fda-approves-atopic-dermatitis\/\">FDA approves Sanofi and Regeneron's new eczema drug<\/a><font size=\"-1\" color=\"#6f6f6f\"><nobr>European Pharmaceutical Review<\/nobr><\/font><\/font><br><font size=\"-1\"><a href=\"http:\/\/news.google.com\/news\/url?sa=t&amp;fd=R&amp;ct2=us&amp;usg=AFQjCNEoPdIxUCllxVQBFHW45xw4J0Sbzg&amp;clid=c3a7d30bb8a4878e06b80cf16b898331&amp;cid=52779447397161&amp;ei=6FHlWJiJJJfD3QGnhIqIAQ&amp;url=https:\/\/www.healthcarepackaging.com\/article\/applications\/healthcare\/fda-approves-37000yr-eczema-drug\">FDA Approves $37,000\/Yr Eczema Drug | Healthcare Packaging<\/a><font size=\"-1\" color=\"#6f6f6f\"><nobr>Healthcare Packaging<\/nobr><\/font><\/font><br><font size=\"-1\" class=\"p\"><\/font><br><font class=\"p\" size=\"-1\"><a class=\"p\" href=\"http:\/\/news.google.com\/news\/more?ncl=dAcHyLJnxxBOujMfoEwPmMHqq-HlM&amp;authuser=0&amp;ned=us\"><nobr><b>all 6 news articles&nbsp;&raquo;<\/b><\/nobr><\/a><\/font><\/div><p><\/p><\/font><\/td><\/tr><\/table><p><!-- Auto Generated --><\/p><p>Read more here:<br><a target=\"_blank\" href=\"http:\/\/www.clinicaladvisor.com\/dermatology-information-center\/fda-approves-dupixent-to-treat-eczema\/article\/647240\/\" title=\"FDA approves Dupixent to treat moderate-to-severe eczema - Clinical Advisor\">FDA approves Dupixent to treat moderate-to-severe eczema - Clinical Advisor<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p> Clinical Advisor FDA approves Dupixent to treat moderate-to-severe eczema Clinical Advisor (HealthDay News) Dupixent (dupilumab) has been approved by the US Food and Drug Administration to treat moderate-to-severe eczema that isn&#39;t well controlled by topical medication. The active ingredient in Dupixent is an antibody (dupilumab) that&nbsp;.. <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/eczema\/fda-approves-dupixent-to-treat-moderate-to-severe-eczema-clinical-advisor\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":["post-186332","post","type-post","status-publish","format-standard","hentry","category-eczema"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/186332"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=186332"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/186332\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=186332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=186332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=186332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}